Big Pharma Companies Acquire Two SoCal Biotech Startups

Keerthi Vedantam

Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.

Big Pharma Companies Acquire Two SoCal Biotech Startups
Photo by Sam Moqadam on Unsplash

Two Southern California biotech startups got swallowed up this week as big pharma benefitted from the record-breaking year of investment in the industry.


Pharmaceutical giant Eli Lilly plucked up a Pasadena startup Protomer Technologies for $1 billion. The company is working on "smart insulin" to treat diabetes.

Another SoCal startup, El Segundo-based Integrity Bio, was acquired by New York drug development company Curia, formerly known as AMRI. Terms of both deals weren't disclosed.

Biotech has been on a tear. Protomer, which last year received an undisclosed funding amount, is one of over a thousand companies who benefited from a banner year in biotech. According to Pitchbook, the industry saw a 60% year-over-year increase in venture capital deal activity in 2020 the largest year-over-year increase ever seen.

Those deals are coming to fruition now, as Protomer and Camarillo-based Integrity Bio, a formulation pharmaceutical upstart, are shedding the need for funding as they get acquired by pharmaceutical companies.

"If Big Pharma wants to start buying assets, more venture capital is going to start pouring into biotech because they know that Big Pharma will be interested in acquiring it down the road," said Bill Bolding, a senior analyst at Provident Healthcare Partners.

Eli Lilly's acquisition of Protomer will give it an even stronger hold on diabetes treatment. Eli Lily's most recent diabetes drug, tirzepatide, outperformed one of its market rivals, and the company is pursuing FDA approval. But glucose-sensing insulin is the next frontier of diabetes treatments, as it has the ability to take into account peoples' unique blood sugar levels.

"With insulin, it's a very complicated drug to use," said Ruth Gimeno, Eli Lilly's vice president of diabetes research. "It's a very efficacious drug, but current insulins are not as safe as we would like them to be. So glucose sensing insulin would just be a complete game changer here."

Curia, a company that formulates and manufactures drugs for other companies, will use Integrity Bio to establish a West Coast presence in the U.S. and get access to the former upstart's slew of clients ranging from startups to Fortune 500 companies. The acquisition is expected to close in the third quarter of 2021.

https://twitter.com/KeerthiVedantam
keerthi@dot.la

Subscribe to our newsletter to catch every headline.

Cadence

How These Ukranian Entrepreneurs Relocated Their Startups to LA and Found Success

Aisha Counts
Aisha Counts is a business reporter covering the technology industry. She has written extensively about tech giants, emerging technologies, startups and venture capital. Before becoming a journalist she spent several years as a management consultant at Ernst & Young.
How These Ukranian Entrepreneurs Relocated Their Startups to LA and Found Success
Joey Mota

Fleeing war and chasing new opportunities, more than a dozen Ukrainian entrepreneurs have landed in Los Angeles, finding an unexpected community in the city of dreams. These entrepreneurs have started companies that are collectively worth more than $300 million, in industries ranging from electric vehicle charging stations to audience monetization platforms to social networks.

Dot.LA spent an evening with this group of Ukrainian citizens, learning what it was like to build startups in Ukraine, to cope with the unimaginable fear of fleeing war, and to garner the resilience to rebuild.

Read moreShow less

Snap’s Fourth Quarter Revenue Was the Company’s Slowest Growth Since Its IPO Six Years Ago

Samson Amore

Samson Amore is a reporter for dot.LA. He holds a degree in journalism from Emerson College and previously covered technology and entertainment for TheWrap and reported on the SoCal startup scene for the Los Angeles Business Journal. Send tips or pitches to samsonamore@dot.la and find him on Twitter @Samsonamore.

​Snap logo over a bunch of snap shots
Sebastian Miño-Bucheli

Snap Inc.’s trend of growing its user base but failing to adequately monetize them continues.

Read moreShow less
https://twitter.com/samsonamore
samsonamore@dot.la
RELATEDEDITOR'S PICKS
LA TECH JOBS
interchangeLA
Trending